Standard dose topiramate — Competitive Intelligence Brief

Standard dose topiramate (Standard dose topiramate) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Anticonvulsant / Antiepileptic agent. Area: Neurology.

marketed Anticonvulsant / Antiepileptic agent Voltage-gated sodium channels, GABA-A receptors, carbonic anhydrase Neurology Small molecule

Target snapshot

Standard dose topiramate (Standard dose topiramate) — Mario Negri Institute for Pharmacological Research. Topiramate blocks sodium channels, enhances GABA activity, and inhibits carbonic anhydrase to reduce neuronal excitability and prevent seizures.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Standard dose topiramate TARGET	Standard dose topiramate	Mario Negri Institute for Pharmacological Research	marketed	Anticonvulsant / Antiepileptic agent	Voltage-gated sodium channels, GABA-A receptors, carbonic anhydrase
Topiramate Standard	Topiramate Standard	Janssen Korea, Ltd., Korea	marketed	Anticonvulsant / Antiepileptic agent	Voltage-gated sodium channels, GABA-A receptors, carbonic anhydrase
zonisamide low dose group	zonisamide low dose group	Eisai Korea Inc.	marketed	Anticonvulsant / Antiepileptic agent	Sodium channels, calcium channels, carbonic anhydrase
Topiramate-Implant	Topiramate-Implant	University of Sao Paulo	marketed	Anticonvulsant / Antiepileptic agent	GABA-A receptor, sodium channels, glutamate receptors
Low dose zonisamide	Low dose zonisamide	Mario Negri Institute for Pharmacological Research	marketed	Anticonvulsant / Antiepileptic agent	Voltage-gated sodium channels, T-type calcium channels, carbonic anhydrase
Carbamazepine-Implant	Carbamazepine-Implant	University of Sao Paulo	marketed	Anticonvulsant / Antiepileptic agent	Voltage-gated sodium channels
Topiramate monotherapy	Topiramate monotherapy	Johnson & Johnson Taiwan Ltd	marketed	Anticonvulsant / Antiepileptic agent	GABA-A receptor; voltage-gated sodium channels

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Anticonvulsant / Antiepileptic agent class)

1. University of Sao Paulo · 2 drugs in this class
2. Mario Negri Institute for Pharmacological Research · 2 drugs in this class
3. Janssen Korea, Ltd., Korea · 1 drug in this class
4. Johnson & Johnson Taiwan Ltd · 1 drug in this class
5. Ministry of Health and Sports, Myanmar · 1 drug in this class
6. Odense University Hospital · 1 drug in this class
7. UCB BIOSCIENCES GmbH · 1 drug in this class
8. University Hospitals Cleveland Medical Center · 1 drug in this class
9. Eisai Korea Inc. · 1 drug in this class
10. Upsher-Smith Laboratories · 1 drug in this class